<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>中睿医药评论 | wechat-feeds</title><link>http://MjM5NDA5MTQ5MQ.favicon.privacyhide.com/favicon.ico</link><description>中睿咨询致力于帮助中国本土大中型企业和具备核心资源的中小成长型企业构建企业战略和战术落地高度融合的一体化的体系。推动企业在明确战略方向指引下，实现持续成长！</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 05 Mar 2021 20:34:20 +0800</pubDate><image><url>http://MjM5NDA5MTQ5MQ.favicon.privacyhide.com/favicon.ico</url><title>中睿医药评论 | wechat-feeds</title><link>http://MjM5NDA5MTQ5MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>迈瑞、迈克、新产业、华大、万孚、万泰等31家上市IVD企业业务线拆解大全</title><link>https://mp.weixin.qq.com/s/rkZgmzFJdSK4NXj9b3qakA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSGKxS0lM96tuAicUn2QJQAVicZg2THRE55RFNgdU0c36yicPPPcxwI6dm8vzafCNnVniallpOM09Dj97g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Fri, 05 Mar 2021 16:36:50 +0800</pubDate></item><item><title>贝达药业三代 EGFR 抑制剂报上市，四代在路上，肺癌靶向药组合发力！</title><link>https://mp.weixin.qq.com/s/rLQkCHKR-w1Ic2io-qG_mA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSGKxS0lM96tuAicUn2QJQAVicQnLsN8LfV5zZ4zN3iacyLZeTefa5pT5ENO40jbr1OyDLUoTibZtabAMw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Fri, 05 Mar 2021 16:36:50 +0800</pubDate></item><item><title>第 2 款国产三代 EGFR 抑制剂！艾力斯医药「伏美替尼」获批上市</title><link>https://mp.weixin.qq.com/s/eNSgRMsn8Tiuc6f2KAIIzg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSEu5yNM8KX7dFJrO8qcGqaZCbqOxXAFMpQSGdp0h7q1bhsiabx3mAfpNfouwQB0xV4WvjQ15JILnMg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:08:28 +0800</pubDate></item><item><title>又一里程碑！百济神州BTK抑制剂泽布替尼在加拿大获批</title><link>https://mp.weixin.qq.com/s/96n81JZ0qR6a3cFXs_EqXw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSEu5yNM8KX7dFJrO8qcGqaZfXTo6c69zVaFAEVnOLmOjs22SfxHfx8tOgWq53DcaRdKic0ZMDON6oA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:08:28 +0800</pubDate></item><item><title>新版国家医保目录正式启用，百济神州PD-1单抗年治疗费用不到7.5万元！</title><link>https://mp.weixin.qq.com/s/bGGSWZfxGX1YFLZArH2gMg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSFicFpuIiaN7cPMlQYzGj6ialuJWzNxRbEb8qUX5UZMqHQWKoickUykzhah32oX6iaS4wE5VO9HnBrIMDA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:25:24 +0800</pubDate></item><item><title>百济神州公布2020年报：有望在全球范围进入集中收获期</title><link>https://mp.weixin.qq.com/s/TROsMLAGRL_-jTTokSh3rw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSFicFpuIiaN7cPMlQYzGj6ialu3bQjgoLfBOib4SFABnOXsU31ne8xABqS2b7QmHyFf5lFmlX1he8l7pg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:25:24 +0800</pubDate></item><item><title>42家国内重点创新药企最新在研管线汇总，快来get！</title><link>https://mp.weixin.qq.com/s/jdwhdGSz_6qavsh9UQhcHQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSE1X3NuuaDKbRIl0VmwBC1BZZG7sJzDvOI1icKO2omr6PpTTu1m6vzJABx6jVSqkiaBXa1bo5VOYTLA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Fri, 26 Feb 2021 16:48:31 +0800</pubDate></item><item><title>百济神州公布2020年报：有望在全球范围进入集中收获期</title><link>https://mp.weixin.qq.com/s/7EANslk5PwUoPUIpYDwZXQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSE1X3NuuaDKbRIl0VmwBC1BtD6DB2bjRMINAXjQsKIy3AdXt06YTUYDZgP9jpia5loBuMNF5w2Vo5g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Fri, 26 Feb 2021 16:48:31 +0800</pubDate></item><item><title>刚刚！第三款国产新冠疫苗，康希诺「Ad5-nCoV」上市申请获受理</title><link>https://mp.weixin.qq.com/s/w9o0rv9IvOCmDsY0NJ98kw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSHPbTezqektMOB8Q1pxOSjauhEV8AeCpQOsdTl8OBIlq64LKOCyQTcIic4YAMnX3XBQXbuAFpJY0tA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Wed, 24 Feb 2021 17:40:32 +0800</pubDate></item><item><title>第三十八批仿制药参比目录制剂发布</title><link>https://mp.weixin.qq.com/s/rnx7h8abLxdUb9_0o3i2cg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HLYCTgiamibSHPbTezqektMOB8Q1pxOSjawW3fHxWicSXicAqdoxGvYBtIoHJwVYmoictwXZQdq3ibKND7XFhOoxIH7A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中睿医药评论]]></content:encoded><pubDate>Wed, 24 Feb 2021 17:40:32 +0800</pubDate></item></channel></rss>